Bevacizumab
|
Better Known as: Avastin
- Marketed By: Genentech & Roche
- Major Indication: Colorectal Cancer
- Drug Class: Vascular Endothelial Growth Factor Inhibitor - Monoclonal Antibody
- Date of FDA Approval (Patent Expiration): 2004 (2019)
- 2009 Sales: $4.8 Billion
- Importance: It is one of the best selling cancer treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| VEGF Inhibitor Pharmacokinetics[1] | |
|---|---|
| Parameter | Bevacizumab |
| Tmax (hr) | 5.17 |
| Cmax (ng/ml) | 284000 |
| Bioavailability (%) | 100 |
| T1/2 (days) | 20 |
| AUC (ug/ml/hr) | 97488 |
| IC50 (nM) | .9 |
| Clearance (L/h) | .0096 |
| Dosage (mg/kg) | 10 |
References
- ↑ Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant. 2007 Mar;22(3):975. Epub 2006 Nov 8. PMID:17093010 doi:10.1093/ndt/gfl664